

Clinical Trial Protocol

Iranian Registry of Clinical Trials

02 Jul 2026

Fertilization rate comparison in IntraCytoplasmic Sperm Injection(ICSI) cycles with second ejaculated sperm sample versus(Testicular sperm extraction) TESE sample in patients with high Deoxyribonucleic acid (DNA) fragmentation index(high DFI)

Protocol summary

Study aim

Comparison of the fertilization rate and the amount of good quality embryos (grade one and two) in couples who could undergo ICSI(Intracytoplasmic sperm Injection), either using TESE(Testicular Sperm Extraction) or second sperm in male subjects with high DFI (DNA Fragmentation Index)and previous ART(Assisted ReproductiveTechnology) failure.

Design

Clinical trial with control group, with parallel groups, randomized, phase 2 on 30 patients. Patients are randomly assigned to one of the study and intervention groups with the help of a random number table and receive the services of the same group.

Settings and conduct

The number of 30 couples referred to Taleghani Hospital with a history of infertility who are candidates for ICSI are examined in the form of intervention and control groups of 15 people.

Participants/Inclusion and exclusion criteria

There are couples who have had a history of at least 1 failure in the previous ART (Assisted Reproductive Technology)and in semen analysis, normospermic men with DFI >30%(DNA Fragmentation Index) Men are between 20 and 50 years old with normal semen Analysis, and women are between 18 and 40 years old. The cause of infertility in all patients is diagnosed only as a male factor

Intervention groups

30infertile couples candidates for ICSI, divided to 2 groups of 15 patients (1:intervention: from the normospermic patients with high DFI within 1 to 3 hours of the first sample, the second sperm sample will be taken) and The control group (under anesthesia during the TESE process, a biopsy will be taken from the testicular tissue and the sperm will be extracted in the

laboratory) are examined.

Main outcome variables

Two groups will be examined and compared in terms of ICSI outcomes, including fertilization rate, the amount of good quality embryos (G1 and G2) and some sperm parameters (concentration, forward movement, normal shape)

General information

Reason for update

Acronym

TESE

IRCT registration information

IRCT registration number: **IRCT20230111057113N2**

Registration date: **2024-01-03, 1402/10/13**

Registration timing: **registered_while_recruiting**

Last update: **2024-01-03, 1402/10/13**

Update count: **0**

Registration date

2024-01-03, 1402/10/13

Registrant information

Name

Samaneh Esmaili

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 4435 2355

Email address

dresmaeili@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-12-22, 1402/10/01

Expected recruitment end date

2024-02-20, 1402/12/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Fertilization rate comparison in IntraCytoplasmic Sperm Injection(ICSI) cycles with second ejaculated sperm sample versus(Testicular sperm extraction) TESE sample in patients with high Deoxyribonucleic acid (DNA) fragmentation index(high DFI)

Public title

Examination of the second sample of ejaculated sperm in patients with high DNA fragmentation(DFI)

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

At least 1 failed ART(Assisted Reproductive technology) attempts women between 18 and 40 years old High DFI levels of more than 30% in semen samples at admission Men between 20and 50 years old

Exclusion criteria:

A male patient with obvious abnormalities noted in the medical history, physical examination, endocrine profile, and evidence of subclinical genital infections, leukocytospermia, cryptorchidism, cancer, history of chemotherapy or radiotherapy, or severe varicocele 2- Women with a history of poor response to ovarian stimulation or meeting the POSEIDON((Patient-Oriented Strategies Encompassing Individualized Oocyte Number) criteria for expected poor responders Pre-implantation genetic screening (PGS), frozen/thawed embryo transfer cycles, Apparent pathology of the uterus or tube 5- People with genetic disorders 6- Male patients with heavy smoking (more than 20 cigarettes per day) 7- Severe endometriosis 8-Patients with sperm freezing

Age

From **20 years** old to **50 years** old

Gender

Both

Phase

2

Groups that have been masked

No information

Sample size

Target sample size: **30**

Randomization (investigator's opinion)

Randomized

Randomization description

patients are randomly placed in one of the two study and intervention groups with the help of a random number table and receive the services related to the same group.

Blinding (investigator's opinion)

Not blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee of Shahid Beheshti University of Medical Sciences

Street address

Taleghani Hosp,Araabi st,Yaman Ave,Chamran,Tehran Highway,

City

Tehran

Province

Tehran

Postal code

1985711151

Approval date

2023-12-13, 1402/09/22

Ethics committee reference number

IR.SBMU.RETECH.REC.1402.548

Health conditions studied**1****Description of health condition studied**

High DNA fragmentation index in sperm of infertile men

ICD-10 code

N46.8

ICD-10 code description

Other male infertility

Primary outcomes**1****Description**

Fertilization rate determination in ICSI (IntraCytoplasmic Sperm Injection)cycles with the second sample of ejaculated sperm in patients with high DFI(DNA Fragmentation Index)

Timepoint

Checking the fertilization rate after 3 days following oocyte injection

Method of measurement

percentage (calculated by dividing the number of 2 pronuclei by the total number of injected eggs)

2

Description

Determining the amount of grade one and two embryos in ICSI cycles with the second sample of ejaculated sperm in patients with high DFI

Timepoint

The number of grade 1 and 2 embryos on day 3 after injection

Method of measurement

Percentage (calculated by dividing the number of grade one and two embryos by the total number of embryos formed)

3

Description

Determination of grade one and two embryos in ICSI cycles with TESE (Testicular Sperm Extraction) samples in patients with high DFI

Timepoint

The number of grade 1 and 2 embryos on day 3 after injection

Method of measurement

Percentage (calculated by dividing the number of grade one and two embryos by the total number of embryos formed)

4

Description

Fertilization rate determination in ICSI cycles with TESE-derived sperm (Testicular Sperm extraction) in patients with high DFI

Timepoint

Checking the fertilization rate after 3 days following oocyte injection

Method of measurement

percentage (calculated by dividing the number of pronuclei by the total number of injected eggs)

Secondary outcomes

1

Description

Investigating the forward motility of sperms in the second sample of ejaculated sperm

Timepoint

The sample within one hour of the first sample

Method of measurement

The percentage of forward-moving spermatozoa to the total spermatozoa observed by light microscopy

2

Description

Examination of other sperm parameters in TESE (Testicular sperm Extraction) sample

Timepoint

Sample immediately after TESE

Method of measurement

The percentage of forward-moving spermatozoa to the

total spermatozoa observed by light microscopy

3

Description

Examination of sperms with normal shape in the second sperm sample

Timepoint

Sample within one to three hours of the first sample

Method of measurement

The percentage of sperms with normal shape to the total sperms with a light microscope

4

Description

Examination of sperms with normal shape in the sample obtained from TESE

Timepoint

Sample immediately after TESE

Method of measurement

The percentage of sperms with normal shape to the total sperms and observed with a light microscope

5

Description

Examining the concentration of sperms in the second sample of ejaculated sperm

Timepoint

The sample within one hour to three after the first sample

Method of measurement

Calculate it under a light microscope and in one cc of ejaculate

6

Description

Investigating the concentration of sperms in the TESE sample

Timepoint

Sample immediately after TESE

Method of measurement

Calculate it under a light microscope and in a cc of semen sample

Intervention groups

1

Description

Control group: TESE sample (TESE sample is prepared from patients under anesthesia)

Category

Treatment - Surgery

2

Description

Intervention group: second sample of ejaculated sperm (patients will be asked to take another sample from the first sample within one to three hours)

Category

Treatment - Other

Recruitment centers**1****Recruitment center****Name of recruitment center**

Taleghani Hospital

Full name of responsible person

Samaneh Esmaeili

Street address

Shahid Arabi St, Yemen St., Chamran Highway, Tehran

City

Tehran

Province

Tehran

Postal code

۱۹۸۵۷۱۱۱۵۱

Phone

+98 21 2303 1307

Fax

+98 21 2243 2570

Email

dresmaeili@gmail.com

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

Full name of responsible person

معاون تحقیقات و فناوری دانشگاه علوم پزشکی شهیدبهشتی

Street addressShahid Taleghani Hospital, Arabi St, Yemen St.,
Chamran Highway, Tehran**City**

Tehran

Province

Tehran

Postal code

۱۹۸۵۷۱۱۱۵۱

Phone

+98 21 2303 1260

Fax

+98 21 2243 2570

Email

dresmaeili@gmail.com

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Shahid Beheshti University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

Full name of responsible person

samaneh esmaeili

Position

Non-faculty specialist doctor

Latest degree

Specialist

Other areas of specialty/work

Gynecology and Obstetrics

Street addressTaleghani Hosp, Araabi st, Yaman Ave, Chamran, Tehran
Highway,**City**

Tehran

Province

Tehran

Postal code

1985711151

Phone

+98 21 2303 1307

Email

dresmaeili@gmail.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

Full name of responsible person

samaneh esmaeili

Position

Non-faculty specialist doctor

Latest degree

Specialist

Other areas of specialty/work

Gynecology and Obstetrics

Street addressTaleghani Hosp, Araabi st, Yaman Ave, Chamran, Tehran
Highway,**City**

Tehran

Province

Tehran

Postal code

Taleghani Hosp, Araab

Phone

+98 21 2303 1307

Email

dresmaeili@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

samaneh esmaeili

Position

Non-faculty specialist doctor

Latest degree

Specialist

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Taleghani Hosp,Araabi st,Yaman Ave,Chamran,Tehran Highway,

City

Tehran

Province

Tehran

Postal code

Taleghani Hosp,Araab

Phone

+98 21 2303 1307

Email

dresmaeili@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Only a part of the data, such as the information related to the main result or the like, can be shared.

When the data will become available and for how long

The access period starts 6 months after the results are published

To whom data/document is available

The data will be available only to researchers working in academic and scientific institutions

Under which criteria data/document could be used

It is allowed to use the documents for the thesis with references

From where data/document is obtainable

Email to this address dresmaeili@gmail.com

What processes are involved for a request to access data/document

After a month, they will receive the results

Comments